Alkem Laboratories , a prominent pharmaceutical company, has recently received a Goods and Services Tax (GST) demand order from the Assistant Commissioner, Central Goods Service Tax Division in Dehradun, Uttarakhand. The order, which covers the financial years 2018-2019 to 2022-2023, alleges excess availment of Input Tax Credit by the company.

Details of the GST Demand Order

The total amount demanded by the tax authorities stands at approximately Rs. 54.94 lakh, which includes both the GST demand and the associated penalty.

Company's Response

Alkem Laboratories has stated that it disagrees with the demand order. The company plans to contest the allegations, indicating its intention to take appropriate action, which may include filing an appeal against the order.

Impact on Operations

In its disclosure to the stock exchanges, Alkem Laboratories emphasized that there is no material impact on its financial, operational, or other activities due to this GST demand order. This statement suggests that the company views the amount in question as manageable within the context of its overall operations.

Compliance and Transparency

It's worth noting that Alkem Laboratories promptly disclosed this information to the stock exchanges, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action demonstrates the company's commitment to transparency and adherence to regulatory requirements.

The development comes as a reminder of the ongoing scrutiny faced by companies in the pharmaceutical sector regarding tax compliance. As the matter unfolds, stakeholders will likely keep a close watch on how Alkem Laboratories addresses this tax issue and its potential implications on the company's financial statements in the coming quarters.

Alkem Laboratories , a prominent Indian pharmaceutical company, has successfully passed a Good Manufacturing Practice (GMP) inspection conducted by Armenia's Ministry of Health at its Sikkim facility. The inspection, which took place from November 21-22, 2025, concluded without any critical or major observations, underscoring the company's commitment to maintaining high-quality manufacturing standards.

Inspection Details

The two-day inspection at Alkem's Sikkim manufacturing facility was carried out by representatives from the Armenian Ministry of Health. The successful completion of this inspection without significant issues is a positive indicator of the company's adherence to international quality standards in pharmaceutical manufacturing.

Implications for Alkem Laboratories

The clearance of this GMP inspection may potentially bolster Alkem Laboratories' reputation in the global pharmaceutical market. It could possibly open doors for expanded market access in Armenia and other countries that recognize Armenian GMP certifications.

Financial Context

While this news primarily focuses on regulatory compliance, it's worth noting Alkem Laboratories' recent financial performance. As of March 2025, the company's consolidated balance sheet showed:

The company has demonstrated growth in total assets and equity, indicating a strong financial position. This financial stability complements its efforts in maintaining high-quality manufacturing practices, as evidenced by the successful GMP inspection.

Conclusion

Alkem Laboratories' successful clearance of the Armenian GMP inspection at its Sikkim facility reinforces its standing as a quality-focused pharmaceutical manufacturer. As the company continues to meet international regulatory standards, it positions itself well for potential market expansions and sustained growth in the global pharmaceutical industry.